Literature DB >> 18562121

Serologically defined Rhipicephalus (Boophilus) microplus larval antigens in BmLF3, a partially pure Sephacryl S-300 fraction of crude larval proteins.

J H Pruett1, P U Olafson, R B Davey.   

Abstract

This report is designed to provide additional information regarding larval soluble proteins toward the planned development of a comprehensive database of Rhipicephalus (Boophilus) microplus proteins that elicit a humoral immune response in cattle as a result of natural ectoparasite infestation. Larval proteins of R. microplus are complex and the protein profile is not dominated by any major proteins. This report focuses upon an S-300 Sephacryl (molecular sieve) column fraction, fraction 3 (BmLF3). With the use of SDS-PAGE (without-2ME) and Western blotting with a composite pool of pre- and post-R. microplus larval infestation antiserum BmLF3 was found to contain 7 apparent common ixodid major antigens (207.3, 171.9, 98.0, 86.5, 65.7, 58.9, and 38.0 kDa), those potentially shared with other ixodid species, and 2 apparent R. microplus specific antigens evidenced by low-level antibody binding in crude BmLF3 (149.4 kDa) and HPLC peak 8 of BmLF3 (116.0 kDa). In addition, BmLF3 contains potent inhibitors of trypsin activity. However, these inhibitors of trypsin did not appear to elicit host antibodies as a result of natural ectoparasite exposure, as defined by Western blotting of reduced and denatured trypsin binding proteins purified by affinity chromatography.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562121     DOI: 10.1016/j.vetpar.2008.04.020

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  1 in total

1.  A comparative study of production performance and animal health practices in organic and conventional dairy systems.

Authors:  Jenevaldo B Silva; Gisele M Fagundes; João P G Soares; Adivaldo H Fonseca; James P Muir
Journal:  Trop Anim Health Prod       Date:  2014-07-12       Impact factor: 1.559

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.